providers, WID®-easy streamlines diagnostics, cutting costs and false alarms. Women benefit from a painless, accessible test that enables earlier, more precise detection. Technology: Powered by advanced DNA methylation research, WID®-easy identifies cancer-specific epigenetic markers. With PCR-based analysis and robust clinical validation, it delivers fast, reliable results that integrate seamlessly into medical workflows. Market Positioning: WID®-easy fills a critical gap as a first-line diagnostic for abnormal uterine bleeding. Its clinical validation, accuracy, and cost-efficiency set it apart from invasive procedures. Its ease of use and scalability position it for widespread adoption. Milestones: Sola Diagnostics launched in Austria and Switzerland in 2024 and expanded to Great Britain and Germany in 2025. UKCA Marking was registered in December 2024. Lauchned in Germany in 2026. So far, private equity investments totaling €3.4M have supported Sola's mission to revolutionize women’s health diagnostics. Moreover, NIHR has provided a GBP 2.2 million grant for a market access study in the UK. In May 2026, WID®-easy Test was included in the German S3-Guidline on Endometrial Cancer.